Deferitrin | GT-56252 | CAS# 239101-33-8 | iron chelator

MedKoo Cat#: 530115 | Name: Deferitrin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deferitrin, also known as GT-56252, is an iron chelator potentially for the treatment of thelassemia and iron overload.

Chemical Structure

Deferitrin

CAS#239101-33-8

Theoretical Analysis

MedKoo Cat#: 530115

Name: Deferitrin

CAS#: 239101-33-8

Chemical Formula: C11H11NO4S

Exact Mass: 253.0400

Molecular Weight: 253.27

Elemental Analysis: C, 52.17; H, 4.38; N, 5.53; O, 25.27; S, 12.66

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 550.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GT-56-252; GT 56-252; GT56-252;; GT-56252; GT 56252; GT56252; Deferitrin; (S)-4'-Hydroxydesazadesferrithiocin;

IUPAC/Chemical Name

4,5-Dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazol-4-(S)-carboxylic acid

InChi Key

OEUUFNIKLCFNLN-LLVKDONJSA-N

InChi Code

InChI=1S/C11H11NO4S/c1-11(10(15)16)5-17-9(12-11)7-3-2-6(13)4-8(7)14/h2-4,13-14H,5H2,1H3,(H,15,16)/t11-/m1/s1

SMILES Code

O=C([C@]1(C)N=C(C2=CC=C(O)C=C2O)SC1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 253.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Donovan JM, Plone M, Dagher R, Bree M, Marquis J. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci. 2005;1054:492-4. doi: 10.1196/annals.1345.071. PMID: 16339704. 2: Barton JC. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders. IDrugs. 2007 Apr;10(4):270-81. PMID: 17390251. 3: Barton JC. Drug evaluation: Deferitrin for iron overload disorders. IDrugs. 2007 Jul;10(7):480-90. PMID: 17642018. 4: Kontoghiorghes GJ. New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert Opin Emerg Drugs. 2006 Mar;11(1):1-5. doi: 10.1517/14728214.11.1.1. PMID: 16503822. 5: Rafati Rahimzadeh M, Rafati Rahimzadeh M, Kazemi S, Moghadamnia AR, Ghaemi Amiri M, Moghadamnia AA. Iron; Benefits or threatens (with emphasis on mechanism and treatment of its poisoning). Hum Exp Toxicol. 2023 Jan- Dec;42:9603271231192361. doi: 10.1177/09603271231192361. PMID: 37526177. 6: Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin. 2006;30(2):329-47. doi: 10.1080/03630260600642674. PMID: 16798657. 7: Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals. 2011 Apr;24(2):239-58. doi: 10.1007/s10534-010-9389-y. Epub 2010 Nov 20. PMID: 21103911; PMCID: PMC3329216. 8: Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr Med Chem. 2005;12(23):2663-81. doi: 10.2174/092986705774463003. PMID: 16305464. 9: Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005 Dec;57(4):547-83. doi: 10.1124/pr.57.4.2. PMID: 16382108. 10: Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. J Med Chem. 2008 Jul 10;51(13):3913-23. doi: 10.1021/jm800154m. Epub 2008 Jun 6. PMID: 18533709; PMCID: PMC2759697. 11: Bergeron RJ, Wiegand J, Weimar WR, McManis JS, Smith RE, Abboud KA. Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier. Chirality. 2003 Aug;15(7):593-9. doi: 10.1002/chir.10248. PMID: 12840823. 12: Bergeron RJ, Wiegand J, McManis JS, McCosar BH, Weimar WR, Brittenham GM, Smith RE. Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. J Med Chem. 1999 Jul 1;42(13):2432-40. doi: 10.1021/jm990058s. PMID: 10395484. 13: Bergeron RJ, Wiegand J, McManis JS, Vinson JR, Yao H, Bharti N, Rocca JR. (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity. J Med Chem. 2006 May 4;49(9):2772-83. doi: 10.1021/jm0508944. PMID: 16640338; PMCID: PMC2547084.